{
  "source": "PA-Med-Nec-Cough-and-Cold.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2141-8\nProgram Prior Authorization/Medical Necessity\nMedication Opioid-containing cough medicines (including but not limited to:\nTuxarin ERTM, codeine/phenylephrine/promethazine,\ncodeine/promethazine, hydrocodone/homatropine, hydrocodone\nbitartrate/guaifenesin, hydrocodone polistirex/chlorpheniramine\npolistirex, hydrocodone bitartrate/chlorpheniramine, Hycodan®)\nP&T Approval Date 3/2018, 3/2019, 8/2019, 8/2020, 8/2021, 3/2023, 3/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nOpioid (codeine or hydrocodone) containing cough and cold products are FDA labeled for\nuse in adults 18 years of age and older. Use of prescription opioid cough and cold\nmedicines containing codeine or hydrocodone should be limited in children younger than\n18 years old due to serious risks associated with use. Coverage for patients age 18 or older\nwill process automatically.\n2. Coverage Criteria:\nA. Authorization\n1. Opioid-containing cough and cold products will be approved based on all of the\nfollowing criteria:\na. Prescriber attests they are aware of FDA labeled contraindications regarding use\nof opioid -containing cough and cold products in patients less than 18 years of age\nand feels the treatment with the requested product is medically necessary\n(Document rationale for use).\n-AND-\nb. Patient does not have a comorbid condition that may impact respiratory depression\n(e.g., asthma or other chronic lung disease, sleep apnea, body mass index > 30)\n-AND-\nc. Patient has tried and failed at least one non-opioid containing cough and cold\nremedy\nAuthorization will be issued for one month.\n3. Additional Clinical Rules:\nNotwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\n© 2025 UnitedHealthcare Services Inc.\n1\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or th",
    " previous claim/medication history, diagnosis codes (ICD-10)\n© 2025 UnitedHealthcare Services Inc.\n1\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Approach to Chronic Cough in Children. UpToDate. October 2024. Accessed March 25,\n2025.\n2. FDA Drug Safety Communication (2018a). FDA requires labeling changes for prescription\nopioid cough and cold medicines to limit their use to adults 18 years and older. US Food and\nDrug Administration website. https://www.fda.gov/drugs/drug-safety-and-availability/fda-\ndrug-safety-communication-fda-requires-labeling-changes-prescription-opioid-cough-and-\ncold. Published January 11, 2018. Accessed March 25, 2025.\nProgram Prior Authorization/Medical Necessity – Opioid-containing cough\nmedicines\nChange Control\nDate Change\n3/2018 New program.\n3/2019 Annual review. Updated references.\n8/2019 Added Tuxarin ER and TussiCaps as in scope. Updated references.\n8/2020 Annual review. Updated references.\n8/2021 Annual review. Updated references. Revised formatting on in scope\ndrugs.\n3/2023 Removed Obredon and Zutripo as they are no longer on the market.\nUpdated references.\n3/2024 Removed Tuzistra XR as it is no longer on the market. Updated\nreferences.\n5/2025 Removed Tussicaps as it is no longer on the market. Added Hycodan.\nUpdated references.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}